Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 7/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377047 | 1.00 | CNR2 (0.39) | CNR2PRKCADGKATLR4LPAR1 | |
| SCHEMBL31573831 | 0.92 | FFAR1 (0.44) | CNR2PRKCADGKA | |
| SCHEMBL9081950 | 0.82 | MGLL (0.43) | CNR2TLR4 | |
| SCHEMBL29519214 | 0.81 | TLR4 (0.38) | CNR2PRKCATLR4 | |
| SCHEMBL9080068 | 0.81 | MGLL (0.42) | CNR2TLR4 | |
| SCHEMBL9081480 | 0.81 | MGLL (0.42) | CNR2TLR4 | |
| SCHEMBL5148037 | 0.81 | PRKCA (0.45) | PRKCA | |
| SCHEMBL905506 | 0.81 | PRKCA (0.45) | PRKCA | |
| SCHEMBL905505 | 0.81 | PRKCA (0.45) | PRKCA | |
| SCHEMBL285222 | 0.79 | PRKCA (0.41) | CNR2PRKCADGKATLR4LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3518950-B1 | METHOD FOR SELECTIVE EXTRACTION OF CANNABINOIDS FROM A PLANT SOURCE | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2025-11-19 | — | — | EP | disclosed |
| US-20240350401-A1 | TOPICAL DELIVERY SYSTEMS FOR ACTIVE COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-24 | — | — | US | disclosed |
| EP-3316860-B1 | DELIVERY SYSTEMS FOR PROPOFOL | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2024-04-10 | — | — | EP | disclosed |
| US-11666618-B2 | Method for selective extraction of cannabinoids from a plant source | YISSUN RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-06 | — | — | US | disclosed |
| US-20220304940-A1 | POLYMERIC SOFT FILMS EMBEDDED WITH NANODOMAINS AND/OR A BIOACTIVE AND METHODS OF PRODUCING SAME | LYOTROPIC DELIVERY SYSTEMS LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| EP-3986383-A1 | POLYMERIC SOFT FILMS EMBEDDED WITH NANODOMAINS AND/OR A BIOACTIVE AND METHODS OF PRODUCING SAME | Lyotropic Delivery Systems Ltd. (IL) | 2022-04-27 | — | — | EP | disclosed |
| US-20220088099-A1 | METHOD FOR EXTRACTION OF AN AGENT FROM A PLANT SOURCE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088099-A1 | METHOD FOR EXTRACTION OF AN AGENT FROM A PLANT SOURCE | GUSB, LIPA, PHOSPHO1 | CNR2 1808/4885PRKCA 1673/4885DGKA 707/4885 |
| US-20240350401-A1 | TOPICAL DELIVERY SYSTEMS FOR ACTIVE COMPOUNDS | VEGFA, MMP10, LIPA | CNR2 1035/4885PRKCA 1022/4885DGKA 45/4885 |
| US-11666618-B2 | Method for selective extraction of cannabinoids from a plant source | CNR2, CNR1, FAAH | CNR2 1/4885PRKCA 2045/4885DGKA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.